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were obtained and ANGIO VOL calculated by area-length method.The SEMI
VOLcorrelated well with the MAN VOL, for EDV:y =0.94 x +4.66 (F =0.94),
for ESV: y = 1.13 x –1.91 (~ =0.92).
Compared VOL data from RT3D and ANGIO are shown below (mean +
SD).
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The regression at EDV of MAN vs. ANGIO was y = 1.16 x -4.13 (~ =
0.95), SEMI vs. ANG10 was y = 1.01 x +4.14 (~ = 0.92). At ESV, corre-
sponding regressions were MAN y = 1.13 x –0.76 (~ = 0,82) and SEMI y
. 1.14 x +1.19 (~ = 0.71). These data indicated that LV VOL calculated by
RT3D using MAN correlated well with ANGIO VOL. The SEMI method is cur-
rently less precise in vivo, These findings are an important step to automated
beat-to-beat RT3D VOL analysis.
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706-1 EffectsofAcuteAngiotensin-ConvetiingEnzyme
Inhibitionon PeripheralVaaodilatorResponsesto
BrsdykininandAcetyichoiinein HeaithySubjects
andPatientawithCoronaryArteryDisease
S. 13enacerraf,C. Carville, S. Adnot, S. Sediame, A. Castaigne,
J.-L. Dubeis-Rande. Henri-Mondor University Hospita/ at Creteil, France
The aim of the study was to asse88 the effects of bcal and acute inhibition
of angiotensin-converting enzyme (ACE) on vasodilation to acetylcholine
(ACh) and bradykinin (BK) in 9 healthy subjects compared to 10 patients
(pts) with coronary artety disaase (CAD). Forearm blood flow (FBF) was
measured by venous owlusion plethysmography during infusion of ACh (40,
80 w~min) and BK (10, 30, 103 pmol/min) into the brachial attery with or
without quinalaprilat (Q) (50 @rein). Vaaodilation (percent change) was
decreased in pta compared to controls with BK (260 +C42% vs 462 + 52%,
p < 0.05) but not with ACh (243 k 74% vs 341 + 67%, NS). Q alone did
not affect FBF in any group. Coinfusion of Q with BK enhanced BK-induced
vasodilation in controls (620 + 4S%vs 462 * 52%, p < 0.05) and in patients
(506 * 67% vs 260 + 42%, p < 0.05). For ACh, Q enhanced ACh-induced
vasodilation in controls (494 * IOOYOvs 341 + 67%, p c 0.05) but not in pts
(233 + 54% VS243 +=74%, NS). LNMMA (8 #mol/min), a specific inhibitor of
NO-synthaee,did not inhibit BK-induced vasodilation. Cone/usiomIn patients
with CAD, although peripheral vasodilation to BK ia blunted, ACE inhibitors
are able to enhance BK-induoed vasodilation in the same extent than in
controls. This vaaodilation is probably distinct from NO pathway.
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m7062 ReducedNitricOxide-DepandantForearmVasodiiationin NormotensiveBiacksComparedto
Whites
C. Cardillo, C.M. Kilcoyne, A.A. Quyyumi, R.O. Cannon, Ill, J.A. Panza.
NHLBI, Bethesda, MD, USA
The physiologic basis of the increased susceptibility of blacksto hypertension
and its complications is unknown. Given the important role of endothelium-
derived nitric oxide (NO) in the regulation of vascular tone and in the pro-
tection against atherosclerosis, we hypothesized that NO activity could be
impaired in blacks. To test this hypothesis, we studied the forearm blood
flow (FBF) response (strain-gauge plethysmography) to intraarterial infusion
of acetylcholine (ACh; 7.5, 15 and 30 pglmin), an endothelium-dependent
vasodilator, and sodium nitroprusside (SNP; 0.8, 1.6 and 3.2 p~min), an
exogenous NO donor given to test the intrinsic endothelium-independent
vaaodilator Capacity of the vessel wall, in 12 normotensive whites (5 men)
and 11 normotensive blacks (5 men) approximately matched for age. No
significant difference was obsewed between whites and blacks in baseline
FBF(3.I *0.6 vs2.9 + 1.2 mUmin/dL, respectively; P= O.59).The response
to ACh was significantly reduced in blacks compared to whites (mezimum
flow: 8.7 + 3 vs 14.4 & 3.7 mUminfdL, respectively; P < 0.001). Of note,
the response to SNP was also significantly blunted in blacks (maximum flow:
6.9 * 2 vs 11.3 k 3.4 mUmirddL in whites; P < 0.001), indicating that the
observed difference in the responae to ACh is likely to be due not to im-
paired NO generation but to impaired responsiveness of vascular smooth
muscle cells to the vasorelaxing effect of NO. This abnormality may con-
tribute to the increased prevalence of hypertension and the higher incidence
of cardiovascular complications in blacks.
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WI safe~and~flica.Yo fNitricoxideand Adenosinein
PredictingNifedipineResponsein Primary
PuimonaryHypertension
M.J. Ricciardi, B.P. Knight, M. Rubenfire. University of Michigan, Ann ArboL
Ml, USA
Primary pulmonary hypertension (PPH) has limited treatment options in-
cluding calcium blockers, IV prostacyclin, and lung transplant. A trial with
incremental dosing of oral nifedipine (nif), 20 mg/hr for 8 hrs or intolerance,
can identify PPH patients who are nif responders, defined as ?20% fall
in mean pulmonary artery pressure (mPA) or pulmonary artery resistance
(PAR). Nif trials carry a risk of profound hypotension and death. Response to
IV adenosine (aden), 50 @/kg q 2 min up to 500 @kg/rein or intolerance,
is reportedly a safe predictor of nif response. Inhaled nitric oxide (NO), 80
ppm for 5 rein, may have similar value. We studied the safety and accuracy
of predicting nif response with NO in 15 and aden in 13 of 19 PPH pts
scheduled to undergo a nif trial the following day. Vasoaefive drugs were
withheld for 24 hre. Average age was 43 + 14 yrs, 74% women. Baseline
mRA 13 k 9 mmHg, mPA 56 + 11 mmHg, CO 4.6+2 Umin, and PAR 10.2
+ 5.0 Wood units. Nine pts received both NO and aden. The mean peak
aden rate was 204 @f@/min (range 100-400). Ten of the 19 pts responded
to nif. All 15 pts tolerated NO although 2 had transient arterial desaturation,
Seven of 15 (46.6%) responded to NO of which 6 responded to nif, The8 NO
non-responders did not respond to nif. NO correctly predicted nif response in
14 of 15 pts (93.3%). All NO responders tolerated nif without complications,
Six of 13 pts (46.1%) were aden responders of which 3 responded to nif. Of
7 non-responders to aden, 2 responded to nif. Aden predicted nif response
in 8 of 13 pts (61.5%). Three aden responders suffered adverse effects with
nif (hypotension in 2, shock and death in 1). Agreement between NO and
aden was poor (Kappa 0.16).
In summary, NO predicts nif res~nse (93% predictive accuracy) and nif
trial safety. In contrast aden, in the dosing schedule used, is less predictive
of nif response (81%), p.045 by McNemar’s, and may encourage high risk
and unneceseew nif triala.
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Flowin Humans
T. Gneochi-Ruscone, R. Lorenzonl, F. Hermanaen, N. Legg, D. Tousoulis,
G. Shepherd 1,P.G,Cemici. MRC G/inica/Sciences Centre, Royal
Postgraduate Medical School, Hammersmith Hospital, London, UK,
1&AXO-Wellcome Ltcl,Greenford, UK
Although ergotemine (E) is beneficial for migraine it may cause myocardial
ischemia. Aim of this study was to ascertain whether E affects myocardial
blood flow (MBF) in humans. A double blind randomized, placebo (P) con-
trolled, crossover study was performed in 15 migraineure (age 54 * 4, 4
males) with no history of ischemic heart disease, normal eehocerdiogram
and negative stress test at high workload. MBF (ml/g/m) wae measured with
positron emission tomography and ’50 Iabelled water at baseline (bas) and
after intravenous dipyridamole (dip; 0.56 mg/kg). Bas and dip MBF were
measured intravenous E (0.25 mg) or P, on two different
days. Bas hemodynamic and MBF data after P and E were not significantly
different. By contrast, E led to significant changes in dip-MBF, coronary va-
sodilator resetve (CVR, dip-MBF/bas-MBF) and minimal eoronay resistance
(rein-CR, mean dip-pressure/dip-MBF, mmHg/ml/m/g).
bas-MBF dip-MBF CVR rein-CR
P * + + 6
E * + 1
Dataareahownasmsan+ SD.(*p <0.01, Pvs E).
Conclusions: E significantly reduces near maximal coronary vasodila-
tion in human subjects without history of iachemic heart disease, probably
through activation of Coronaryserotonergic and/or q -adrenergic receptors.
This could explain the ischemic effect of E in the heart.
